Eisai\'s Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China

Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China

TOKYO, July 17, 2019 - (JCN Newswire) - Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate) for use in the treatment of patients with loca...

More From BioPortfolio on "Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China"